LH

Business Context and Reporting Period

Company: Laboratory Corporation of America Holdings (LabCorp)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Business Overview: LabCorp operates as a leading provider of clinical laboratory testing services, including routine, genomic, and esoteric testing. The company reported continued growth in its Managed Care business and a strategic shift toward higher-priced genomic and esoteric tests during the period.

Key Financial Metrics

Note: Total Debt calculated as Short-term borrowings ($120.8M) + Long-term debt ($1,291.1M).

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 3.6% for the quarter and 4.2% for the six-month period compared to 2008. Growth was driven by Managed Care business expansion and a shift in test mix to higher-priced genomic and esoteric testing.
• Profitability: Operating income rose 25.4% for the quarter and 11.2% for the six-month period. Net earnings attributable to LabCorp increased 30.9% (quarter) and 14.8% (six months).
• Expense Management: Selling, general, and administrative (SG&A) expenses decreased 10.8% for the quarter, primarily due to a significant reduction in bad debt expense compared to a $45.0 million provision increase in the prior year.
• Restructuring: Net restructuring charges were $10.2 million for the quarter, down from $16.0 million in the prior year, due to favorable settlements on lease buyouts and lower-than-planned severance costs.
• Debt Reduction: The company redeemed approximately 50% of its zero-coupon subordinated notes ($369.5 million principal) in the second quarter, utilizing $289.4 million in cash.
• Foreign Operations: Net sales from the Ontario, Canada joint venture decreased 8.2% (quarter) and 10.6% (six months) in USD terms due to a stronger U.S. dollar, though volume increased in Canadian dollars.

Guidance, Outlook, and Risks

• Acquisition: In June 2009, LabCorp entered a definitive agreement to acquire Monogram Biosciences, Inc. for approximately $106.7 million in equity value. Closing is expected in the third quarter of 2009.
• Capital Expenditures: The company expects capital expenditures of approximately $130.0 million for the full year 2009, funded by operating cash flow and credit facilities.
• Pension Obligations: Due to market performance in 2008, projected pension expense is expected to increase from $19.5 million in 2008 to $33.8 million in 2009. The company contributed $45.6 million to its defined benefit plan in the first half of 2009.
• Liquidity: The company maintains a $95.2 million authorization for share repurchases, though no shares were purchased in the first half of 2009. Management believes current liquidity is sufficient to meet short- and long-term needs.
• Risks: Key risks include changes in federal/state reimbursement policies, potential adverse results from government audits (including a qui tam lawsuit regarding California Medicaid billing), and the impact of the Lehman Brothers bankruptcy on the company's revolving credit facility commitment.

Investor Verification Checklist

• Debt Redemption Impact: Verify the cash outflow of $289.4 million for the zero-coupon note redemption and its effect on liquidity.
• Bad Debt Reversal: Confirm the sustainability of the reduced bad debt expense, which was heavily influenced by a one-time $45.0 million provision in the prior year.
• Monogram Acquisition: Monitor the closing status of the Monogram Biosciences acquisition and potential integration costs.
• Legal Proceedings: Review updates on the California Medicaid qui tam lawsuit and other government billing audits.
• Foreign Exchange: Assess the ongoing impact of the strong U.S. dollar on the Ontario joint venture's reported revenue.
• Pension Funding: Track future pension contributions required to meet the increased projected expense of $33.8 million for 2009.